Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C
Journal of Viral Hepatitis · 2023
DOI: 10.1111/jvh.13859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Mei Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms, Hepatitis C. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: AbbVie, Centers for Disease Control and Prevention, Gilead Sciences.
Abstract (Originalsprache)
Chronic hepatitis C (HCV) is a primary cause of hepatocellular carcinoma (HCC). Although antiviral treatment reduces risk of HCC, few studies quantify the impact of treatment on long‐term risk in the era of direct‐acting antivirals (DAA). Using data from the Chronic Hepatitis Cohort Study, we evaluated the impact of treatment type (DAA, interferon‐based [IFN], or none) and outcome (sustained virological response [SVR] or treatment failure [TF]) on risk of HCC. We then developed and validated a predictive risk model. 17186 HCV patients were followed until HCC, death or last follow‐up. We used extended landmark modelling, with time‐varying covariates and propensity score justification and generalized estimating equations with a link function for discrete time‐to‐event data. Death was considered a competing risk. We observed 586 HCC cases across 104,000 interval‐years of follow‐up. SVR from DAA or IFN‐based treatment reduced risk of HCC (aHR 0.13, 95% CI 0.08–0.20; and aHR 0.45, 95% CI 0.31–0.65); DAA SVR reduced risk more than IFN SVR (aHR 0.29, 95% CI 0.17–0.48). Independent of treatment, cirrhosis was the strongest risk factor for HCC (aHR 3.94, 95% CI 3.17–4.89 vs. no cirrhosis). Other risk factors included male sex, White race and genotype 3. Our six‐variable predictive model had ‘excellent’ accuracy (AUROC 0.94) in independent validation. Our novel landmark interval‐based model identified HCC risk factors across antiviral treatment status and interactions with cirrhosis. This model demonstrated excellent predictive accuracy in a large, racially diverse cohort of patients and could be adapted for ‘real world’ HCC monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan, USA.
- Department of Gastroenterology and Hepatology, Henry Ford Health, Detroit, Michigan, USA.
- School of Medicine, Wayne State University, Detroit, Michigan, USA.
- Department of Health Policy and Health Services Research, Henry Ford Health, Detroit, Michigan, USA.
- Center for Integrated Health Care Research, Kaiser Permanente Hawaii, Honolulu, Hawaii, USA.
- Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
ORCID-Profile: Mei Lu, Sheri Trudeau
Förderung
- AbbVie
- Centers for Disease Control and Prevention
- Gilead Sciences
- GlaxoSmithKline
Zitieren
APA
Lu, M., Salgia, R., Li, J., Trudeau, S., Rupp, L. B., Wu, T., Daida, Y. G., Schmidt, M. A., & Gordon, S. C. (2023). Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13859
Vancouver
Lu M, Salgia R, Li J, Trudeau S, Rupp LB, Wu T, et al. Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13859
BibTeX
@article{Lu2023,
author = {Lu, Mei and Salgia, Reena and Li, Jia and Trudeau, Sheri and Rupp, Loralee B and Wu, Trueman and Daida, Yihe G and Schmidt, Mark A and Gordon, Stuart C},
title = {Dynamic risk assessment for hepatocellular carcinoma in patients with chronic hepatitis C},
journal = {Journal of Viral Hepatitis},
year = {2023},
doi = {10.1111/jvh.13859}
}
EUVIMED